Fiche publication
Date publication
janvier 2015
Journal
PloS one
Auteurs
Membres identifiés du Cancéropôle Est :
Dr FEIN Francine
,
Pr LEPAGE Côme
Tous les auteurs :
Serdjebi C, Gagnière J, Desramé J, Fein F, Guimbaud R, François E, André T, Seitz JF, Montérymard C, Arsene D, Volet J, Abakar-Mahamat A, Lecomte T, Guerin-Meyer V, Legoux JL, Deplanque G, Guillet P, Ciccolini J, Lepage C, Dahan L
Lien Pubmed
Résumé
Because cytidine deaminase (CDA) is the key enzyme in gemcitabine metabolism, numerous studies have attempted to investigate impact of CDA status (i.e. genotype or phenotype) on clinical outcome. To date, data are still controversial because none of these studies has fully investigated genotype-phenotype CDA status, pharmacokinetics and clinical outcome relationships in gemcitabine-treated patients. Besides, most patients were treated with gemcitabine associated with other drugs, thus adding a confounding factor. We performed a multicenter prospective clinical trial in gemcitabine-treated patients which aimed at investigating the link between CDA deficiency on the occurrence of severe toxicities and on pharmacokinetics, and studying CDA genotype-phenotype relationships.
Mots clés
Adenocarcinoma, drug therapy, Adult, Aged, Aged, 80 and over, Antimetabolites, Antineoplastic, adverse effects, Biomarkers, Pharmacological, metabolism, Cytidine Deaminase, metabolism, Deoxycytidine, adverse effects, Female, Humans, Male, Middle Aged, Pancreatic Neoplasms, drug therapy, Treatment Outcome
Référence
PLoS ONE. 2015 ;10(8):e0135907
